147 related articles for article (PubMed ID: 33209888)
1. Correlation between the coexpression of zinc finger and SCAN domain-containing protein 31 and transcriptional activator with PDZ-binding motif and prognosis in hepatocellular carcinoma.
Liu Q; Shi Z; Liu X; Xiao H
Ann Transl Med; 2020 Oct; 8(20):1308. PubMed ID: 33209888
[TBL] [Abstract][Full Text] [Related]
2. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma.
Xiao H; Jiang N; Zhou B; Liu Q; Du C
Cancer Sci; 2015 Feb; 106(2):151-9. PubMed ID: 25495189
[TBL] [Abstract][Full Text] [Related]
3. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
[TBL] [Abstract][Full Text] [Related]
4. Silencing of TAZ inhibits the motility of hepatocellular carcinoma cells through autophagy induction.
Zhou W; Weng J; Wu K; Xu X; Wang H; Zhang J; Zhao C; Yang J; Zhang Y; Shen W
Cancer Manag Res; 2019; 11():8743-8753. PubMed ID: 31576176
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomics analysis revealed that TAZ regulates the proliferation of KIRC cells through mitophagy.
He Z; Shi J; Zhu B; Tian Z; Zhang Z
BMC Cancer; 2024 Feb; 24(1):229. PubMed ID: 38373978
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif.
Li J; Fang L; Yu W; Wang Y
Oncol Lett; 2015 Apr; 9(4):1971-1975. PubMed ID: 25789078
[TBL] [Abstract][Full Text] [Related]
7. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
8. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
9. Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma.
Guo Y; Pan Q; Zhang J; Xu X; Liu X; Wang Q; Yi R; Xie X; Yao L; Liu W; Shen L
J Cell Biochem; 2015 Nov; 116(11):2465-75. PubMed ID: 25650113
[TBL] [Abstract][Full Text] [Related]
10. TAZ-regulated expression of IL-8 is involved in chemoresistance of hepatocellular carcinoma cells.
Zhang H; Yu QL; Meng L; Huang H; Liu H; Zhang N; Liu N; Yang J; Zhang YZ; Huang Q
Arch Biochem Biophys; 2020 Oct; 693():108571. PubMed ID: 32898567
[TBL] [Abstract][Full Text] [Related]
11. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY
Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869
[TBL] [Abstract][Full Text] [Related]
12. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
[TBL] [Abstract][Full Text] [Related]
13. The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness.
Park H; Lee Y; Lee K; Lee H; Yoo JE; Ahn S; Park YN; Kim H
Pathol Oncol Res; 2021; 27():604600. PubMed ID: 34257565
[No Abstract] [Full Text] [Related]
14. Validation of chemical compound library screening for transcriptional co-activator with PDZ-binding motif inhibitors using GFP-fused transcriptional co-activator with PDZ-binding motif.
Nagashima S; Maruyama J; Kawano S; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Nishina H; Hata Y
Cancer Sci; 2016 Jun; 107(6):791-802. PubMed ID: 27009852
[TBL] [Abstract][Full Text] [Related]
15. The Hippo Pathway Effector Transcriptional Co-activator With PDZ-Binding Motif Correlates With Clinical Prognosis and Immune Infiltration in Colorectal Cancer.
Wang Y; Nie H; Li H; Liao Z; Yang X; He X; Ma J; Zhou J; Ou C
Front Med (Lausanne); 2022; 9():888093. PubMed ID: 35865173
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA LOC107985656 represses the proliferation of hepatocellular carcinoma cells through activation of the tumor-suppressive Hippo pathway.
Zeng Y; Xu Q; Xu N
Bioengineered; 2021 Dec; 12(1):7964-7974. PubMed ID: 34565286
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-185 suppresses pancreatic cell proliferation by targeting transcriptional coactivator with PDZ-binding motif in pancreatic cancer.
Xia D; Li X; Niu Q; Liu X; Xu W; Ma C; Gu H; Liu Z; Shi L; Tian X; Chen X; Zhang Y
Exp Ther Med; 2018 Jan; 15(1):657-666. PubMed ID: 29399068
[TBL] [Abstract][Full Text] [Related]
18. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
19. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells.
Higashi T; Hayashi H; Ishimoto T; Takeyama H; Kaida T; Arima K; Taki K; Sakamoto K; Kuroki H; Okabe H; Nitta H; Hashimoto D; Chikamoto A; Beppu T; Baba H
Br J Cancer; 2015 Jul; 113(2):252-8. PubMed ID: 26125451
[TBL] [Abstract][Full Text] [Related]
20. [Expression of transcriptional coactivator with PDZ-binding motif (TAZ) in colon cancer tissues and its clinical significance].
Zeng C; Huang L; Zheng Y; Huang H; Chen L; Chi L
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Nov; 18(11):1154-7. PubMed ID: 26616814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
